English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 9 June 2020, 20:00 HKT/SGT
Share:
    

Source: Avance Clinical
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020

ADELAIDE, AUS, June 9, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. Importantly in Australia, despite the global COVID-19 pandemic, no healthy volunteer studies have been suspended, and only 27 Phase 1 or 2 studies were temporarily put on hold for various reasons (TrialTrove, 9 June 2020).

Avance Clinical commended the Australian industry for exceptional COVID-19 management which has meant Australia leads the world in maintaining clinical trials business as usual.

Avance Clinical's Chief Strategy Officer, Ben Edwards presented at BIO Digital 2020 today on the many benefits of running trials in Australia.

Watch the Avance Clinical BIO Digital presentation On Demand here.
https://www.bio.org/events/bio-digital/sessions/search?name=Avance%20Clinical

Mr Edwards said: "Approximately 96% of our work is supporting small to medium-sized biotechnology companies executing Phase 1 and Phase 2 trials. Our client base currently extends across North America, Canada, New Zealand, Europe and Asia.

Australia is a well-established location for international clinical trials and our management of the COVID-19 crisis has made it an even more attractive trials destination."

Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.

In addition to the impressive COVID-19 management, a key factor in sponsor demand is the speed, access to high quality sites and attractive cost of running trials in Australia including:

- The Australian Government financial rebate of 43.5% on clinical trial spend
- No IND required for clinical trials and streamlined regulatory processes
- Advanced medical, research & scientific community, leading investigators & KOLs, modern medical facilities

Watch the video: How we work during the COVID-19 pandemic here. https://tinyurl.com/yc2z6kjj

Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialised patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson


Topic: Clinical Trial Results
Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Avance Clinical Related News
June 4, 2024 22:56 HKT/SGT
BIO24에서 발표된 새로운 연구에서 내부 규제 사항을 갖춘 CRO는 생명공학 기업에게 30%의 절감을 제공하고, 시간을 절반으로 줄이며, 위험을 줄입니다
June 4, 2024 22:46 HKT/SGT
新研究發現,具有內部監管事務的CRO公司為生物技術公司節省30%的成本,縮短時間線一半,降低風險
June 4, 2024 22:25 HKT/SGT
新研究发现,具有内部监管事务的CRO公司为生物技术公司节省30%的成本,缩短时间线一半,降低风险
June 4, 2024 22:00 HKT/SGT
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 1, 2024 06:00 HKT/SGT
Avance Clinical透過與Julius Clinical合作,在歐洲擴展專門的中樞神經系統、心血管代謝和罕見疾病的CRO服務
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575